- Home
- PRTA vs AQST Comparison
PRTA vs AQST Comparison
Compare PRTA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- AQST
- Stock Information
- Founded
- PRTA 2012
- AQST 2004
- Country
- PRTA Ireland
- AQST United States
- Employees
- PRTA N/A
- AQST N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- PRTA Health Care
- AQST Health Care
- Exchange
- PRTA Nasdaq
- AQST Nasdaq
- Market Cap
- PRTA 472.1M
- AQST 390.4M
- IPO Year
- PRTA N/A
- AQST 2018
- Fundamental
- Price
- PRTA $8.20
- AQST $3.77
- Analyst Decision
- PRTA Buy
- AQST Strong Buy
- Analyst Count
- PRTA 10
- AQST 6
- Target Price
- PRTA $14.86
- AQST $10.67
- AVG Volume (30 Days)
- PRTA 1.2M
- AQST 1.4M
- Earning Date
- PRTA 08-04-2025
- AQST 08-11-2025
- Dividend Yield
- PRTA N/A
- AQST N/A
- EPS Growth
- PRTA N/A
- AQST N/A
- EPS
- PRTA N/A
- AQST N/A
- Revenue
- PRTA $10,341,000.00
- AQST $44,132,000.00
- Revenue This Year
- PRTA N/A
- AQST N/A
- Revenue Next Year
- PRTA $389.77
- AQST $38.71
- P/E Ratio
- PRTA N/A
- AQST N/A
- Revenue Growth
- PRTA N/A
- AQST N/A
- 52 Week Low
- PRTA $4.32
- AQST $2.12
- 52 Week High
- PRTA $22.83
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- PRTA 58.73
- AQST 44.00
- Support Level
- PRTA $8.05
- AQST $3.85
- Resistance Level
- PRTA $8.73
- AQST $4.13
- Average True Range (ATR)
- PRTA 0.38
- AQST 0.25
- MACD
- PRTA -0.05
- AQST -0.03
- Stochastic Oscillator
- PRTA 47.62
- AQST 13.79
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.